Symbols

GTHX(Delisted)

G1 Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 2

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GTHX

G1 Therapeutics, Inc.

A commercial-stage biopharmaceutical company that developing novel small molecule therapeutics for the treatment of cancer

Industry

Established Date

05/19/2008

Listing Date

05/17/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

100

Fiscal Year Ends

12-31

Website

www.g1therapeutics.com

Security Type

Common stock

Office address

700 Park Offices Drive, Suite 200, Research Triangle Park, NC 27709

Business

Introduction

G1 Therapeutics, Inc., was incorporated under the laws of the State of Delaware on May 19, 2008 under the name "G-Zero Therapeutics, Inc.". In September 2012, they changed their name to "G1 Therapeutics, Inc.". The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapies for the treatment of cancer patients. COSELA (trilaciclib), the first product approved by the US Food and Drug Administration, is the first and only therapy proven to actively help protect bone marrow from damage from chemotherapy (bone marrow protection) and the first innovation in managing bone marrow protection in decades. In July 2022, COSELA (Trasilib Hydrochloride for Injection) was conditionally approved by the National Medical Products Administration to be marketed in China.

Company Financials

EPS

GTHX has released its 2024 Q2 earnings. EPS was reported at -0.1, versus the expected -0.16, beating expectations. The chart below visualizes how GTHX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GTHX has released its 2024 Q2 earnings report, with revenue of 16.55M, reflecting a YoY change of -60.97%, and net profit of -5.47M, showing a YoY change of -162.79%. The Sankey diagram below clearly presents GTHX's revenue sources and cost distribution.